GSK paid smaller companies to delay generic versions of paroxetine, says fair trade bodyBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f2566 (Published 22 April 2013) Cite this as: BMJ 2013;346:f2566
- Clare Dyer
The UK Office of Fair Trading (OFT) has accused GlaxoSmithKline of breaching competition law and abusing its dominant market in the supply of an antidepressant.
The competition watchdog said that it would investigate a series of deals the United Kingdom’s biggest drug maker made between 2001 and 2004 with three smaller companies that wanted to market cheaper generic versions of GSK’s blockbuster drug paroxetine (which it markets as Seroxat).
The OFT alleges that GSK accused the generic manufacturers of infringeing its patents and, to settle the disputes, struck so called “pay for delay” deals, in …
Log in using your username and password
Log in through your institution
Sign up for a free trial